Guidelines on Germline Testing for Urologic Tumor Syndromes

In the expanding precision medicine landscape, along with improvements in and the availability of testing, the use of genetics in the evaluation and treatment of patients has increased significantly. Multiple urologic cancers in different organ systems associ-ated with an inherited gene mutation have been described. As these mutations can impact screening and treatment decisions for patients and their families, it is important for providers to be familiar with the current guidelines for germline testing. Here we summarize the current guidelines regarding germline testing for patients with suspected urologic tumor syndromes.Patient summary: Several cancers of the genitourinary tract can be associated with inherited genetic mutations. Knowledge of when to test for these mutations has impli-cations for both treatment and screening of patients and their family members at risk of genitourinary cancers.(c) 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Automated summary

In the expanding field of precision medicine, the use of genetics in the evaluation and treatment of patients with urologic cancers associated with inherited genetic mutations has significantly increased. Familiarity with current guidelines for germline testing is important for impacting screening and treatment decisions.